Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
Status:
RECRUITING
Trial end date:
2027-07-21
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.